What you pay for a ChondroFiller injection

Three published guide costs set the baseline for ChondroFiller injection in the UK. London Cartilage Clinic prices the treatment at £3,000 for one box, £5,500 for two boxes, and £8,000 for three boxes. The same structure applies whichever joint is being treated — knee, hip, ankle, shoulder, or any of the other eligible joints — so patients do not face a different tariff based on anatomy alone.

The tier that applies depends on how much product the defect requires. Most focal cartilage lesions are treated with a single box, but larger surface areas or multi-compartment involvement may call for two or three. That decision is made at clinical assessment rather than by the patient in advance: a treating clinician maps the defect — typically using imaging — and advises which tier is appropriate before any commitment is made.

These are guide costs confirmed by London Cartilage Clinic at 66 Harley Street, which was the first UK clinic to offer ChondroFiller as a standalone injection pathway. No other UK provider has published equivalent pricing, so these figures represent the current UK market reference point for the treatment. They are not fixed quotes; the actual recommendation follows a structured assessment of defect size and joint condition.

What the price includes

Each of the three price tiers is fully bundled. The guide cost covers the initial consultation, ultrasound imaging on the day, the ChondroFiller product itself, the injection procedure, intravenous antibiotic prophylaxis, and a six-week follow-up appointment — no element is charged separately within that package.

The antibiotic cover is administered at the time of injection as a routine precaution against infection; patients who have not encountered this in other outpatient procedures should expect a brief IV line as part of the appointment rather than an unexpected addition to their care.

The ChondroFiller product — a CE-marked Class III medical device imported from Germany — accounts for the largest share of the guide cost. As a regulated implantable device, its supply carries import and regulatory compliance costs that distinguish it from more familiar in-clinic injectables, which helps explain the overall price level relative to standard joint injections.

The procedure itself takes approximately 30 to 45 minutes and is carried out under ultrasound guidance in an outpatient setting. No hospital admission, theatre booking, or general anaesthetic is required.

Patients who have already had MRI or other diagnostic imaging performed elsewhere should clarify at the point of booking whether that imaging is sufficient for clinical assessment or whether additional imaging will be arranged — and, if so, whether it falls within the bundle or attracts a separate charge.

CCSD codes and private insurance coverage

Private insurance may contribute to the cost, but the extent of that contribution depends on how the procedure is coded and what a patient's specific policy covers — neither is straightforward.

ChondroFiller injection maps to two recognised CCSD procedure codes. W3111 (cartilage regeneration with collagen scaffold) is the principal code and covers the ChondroFiller implant itself. W8500 (arthroscopy) applies only where the procedure is delivered arthroscopically in a theatre setting; it is not relevant to the current outpatient, ultrasound-guided injection pathway offered at London Cartilage Clinic. Patients receiving the injectable route should not expect W8500 to feature in their pre-authorisation request.

Both codes appear on the fee schedules of several UK insurers. As of October 2025, pre-authorisation approvals have most commonly been reported with Bupa, Aviva, and WPA. That said, inclusion on a fee schedule does not mean automatic funding: policy terms, benefit limits, and individual underwriting decisions all affect the outcome.

Partial coverage is a realistic result. Some insurers may agree to fund the arthroscopy component under W8500 while declining the implant cost under W3111 — the more significant of the two charges. Patients should not assume that a partial approval covers the full procedure cost.

Written pre-authorisation is always required before treatment proceeds and must be obtained in advance; retrospective claims are unlikely to be honoured. Before booking, contact your insurer directly, provide both CCSD codes, and confirm in writing precisely which elements of the procedure — and which codes — fall within your approved benefit. The treating clinic can advise on the coding if needed.

NHS availability and self-funding

ChondroFiller is not commissioned by NHS England and is not available through GP referral to an NHS hospital trust. No integrated care board currently funds it as a routine treatment, and there is no established pathway for accessing it via the public system.

Self-funded private treatment is therefore the only current access route in the UK. The guide costs set out in the opening section reflect that reality — patients should budget on a self-funded basis from the outset.

Private medical insurance does not list ChondroFiller as a standard benefit, though individual policies may contribute via the CCSD coding pathway described in the section above. Treat any insurance recovery as a possibility to pursue in parallel, not a default entitlement.

Combination therapy and advanced-OA pricing

For patients with Kellgren-Lawrence Grade III or IV osteoarthritis — where cartilage loss is more extensive — a single-box ChondroFiller injection may be insufficient on its own. Two higher-tier packages address this more complex clinical picture.

Dual-injection package (£6,000). ChondroFiller combined with Arthrosamid, a polyacrylamide hydrogel, is available as a single-session protocol for Grade III/IV disease. The two products are not interchangeable and should not be read as doing the same thing: ChondroFiller is the regenerative component, working through acellular matrix-induced chondrogenesis to recruit the patient's own progenitor cells into a collagen scaffold. Arthrosamid is a non-regenerative hydrogel used here for a separate therapeutic role — joint cushioning and load management — rather than tissue repair. The mechanisms are distinct and the combination is designed to address different aspects of the same joint problem.

Tri-active package (£11,000). For the most severe or complex presentations, autologous mesenchymal stem cells (MSC) can be added as a third component, at a £5,000 premium over the dual package. Each element continues to operate through its own mechanism; this is not a single combined product.

Neither package is a consumer-selectable upgrade. Which protocol is appropriate — if any — depends on defect extent, OA grade, and clinical assessment of the joint as a whole.

A longitudinal lifetime programme, structured around annual maintenance and bi-annual top-up injections, is also available. Specific fees for this programme are not publicly listed; patients planning for long-term joint management are best placed to raise it at their initial assessment appointment.

Getting a cost-confirmed assessment

The guide costs above set a framework, but the figure that matters is the one confirmed after clinical assessment — because the number of boxes required, and whether a combination protocol is appropriate, can only be determined once defect extent has been evaluated. That assessment takes place at 66 Harley Street, where suitability and the applicable pricing tier are established before any treatment is agreed.

Patients with private medical insurance should review the insurance section above before booking and obtain written pre-authorisation from their insurer in advance.

To arrange an assessment, visit londoncartilage.com.